The Lung Cancer Mutation Panel offers a keystone to personalized medicine and tests for mutations in all three oncogenes (EGFR, KRAS, ALK). It is a personalized diagnostic tool that helps determine patient’s sensitivity or resistance to multiple EGFR TKIs and ALK inhibitors. It helps in determinig the targeted therapies for non-small cell lung cancer (NSCLC) patients.